Published in Int J Biomed Sci on December 01, 2011
TM4: a free, open-source system for microarray data management and analysis. Biotechniques (2003) 38.02
Surfing the p53 network. Nature (2000) 35.36
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature (1992) 25.54
STRING 8--a global view on proteins and their functional interactions in 630 organisms. Nucleic Acids Res (2008) 20.62
The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat (2002) 12.39
Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol (2008) 11.05
Role of angiogenesis in tumor growth and metastasis. Semin Oncol (2002) 9.77
Mutual information relevance networks: functional genomic clustering using pairwise entropy measurements. Pac Symp Biocomput (2000) 8.02
Cancer's molecular sweet tooth and the Warburg effect. Cancer Res (2006) 7.24
A comprehensive pathway map of epidermal growth factor receptor signaling. Mol Syst Biol (2005) 5.68
Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res (1994) 5.64
Dynamic modularity in protein interaction networks predicts breast cancer outcome. Nat Biotechnol (2009) 5.41
Predicting disease genes using protein-protein interactions. J Med Genet (2006) 4.10
Identification of tumor-initiating cells in a p53-null mouse model of breast cancer. Cancer Res (2008) 3.45
Molecular biology of mammalian glucose transporters. Diabetes Care (1990) 3.33
A subset of p53-deficient embryos exhibit exencephaly. Nat Genet (1995) 3.24
Disease candidate gene identification and prioritization using protein interaction networks. BMC Bioinformatics (2009) 3.03
High-frequency developmental abnormalities in p53-deficient mice. Curr Biol (1995) 2.57
Recent advances in p53 research: an interdisciplinary perspective. Cancer Gene Ther (2008) 1.88
p53 regulation of metabolic pathways. Cold Spring Harb Perspect Biol (2009) 1.79
Genome-wide association studies: progress and potential for drug discovery and development. Nat Rev Drug Discov (2008) 1.45
Discovery and scoring of protein interaction subnetworks discriminative of late stage human colon cancer. Mol Cell Proteomics (2008) 1.43
Relationship between expression of Bcl-2 genes and growth factors in ischemic acute renal failure in the rat. J Am Soc Nephrol (2000) 1.36
HIF-1alpha and p53: the ODD couple? Trends Biochem Sci (2005) 1.12
p53 and its downstream proteins as molecular targets of cancer. Mol Carcinog (2006) 1.12
Association of immunohistochemical staining for p53 with metastatic progression and poor survival in patients with renal cell carcinoma. J Natl Cancer Inst (1994) 1.03
A role for p53 in terminal epithelial cell differentiation. J Clin Invest (2002) 0.99
Value of p53 as a prognostic marker in histologic subtypes of renal cell carcinoma: a systematic analysis of primary and metastatic tumor tissue. Urology (2004) 0.97
Impact of genetics on the diagnosis and treatment of renal cancer. Curr Urol Rep (2011) 0.87
Glucose transporter expression and the potential role of fructose in renal cell carcinoma: A correlation with pathological parameters. Mol Med Rep (2011) 0.81
p53 mutations and MDM-2 amplification in renal cell cancers. Mod Pathol (1994) 0.78
Designing logical rules to model the response of biomolecular networks with complex interactions: an application to cancer modeling. IEEE/ACM Trans Comput Biol Bioinform (2011) 0.78
Relationship between expression of p53 protein and tumor subtype and grade in renal cell carcinoma. Urol J (2006) 0.78
Expression of Notch1 to -4 and their ligands in renal cell carcinoma: a tissue microarray study. Cancer Genomics Proteomics (2011) 0.90
Phase II randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer. Ann Oncol (2012) 0.90
Phase II open-label study of erlotinib in combination with gemcitabine in unresectable and/or metastatic adenocarcinoma of the pancreas: relationship between skin rash and survival (Pantar study). Ann Oncol (2011) 0.89
Fructose transporter GLUT5 expression in clear renal cell carcinoma. Oncol Rep (2010) 0.85
Phase II study of irinotecan as first-line chemotherapy for patients with advanced colorectal carcinoma. Cancer (2001) 0.81
Searching for Hif1-α interacting proteins in renal cell carcinoma. Clin Transl Oncol (2012) 0.80
Phase II trial of miniDOX (reduced dose docetaxel-oxaliplatin-capecitabine) in "suboptimal" patients with advanced gastric cancer (AGC). TTD 08-02. Cancer Chemother Pharmacol (2014) 0.79
Recommendations and expert opinion on the adjuvant treatment of colon cancer in Spain. Clin Transl Oncol (2011) 0.78
Multiple biomarker tissue arrays: A computational approach to identifying protein-protein interactions in the EGFR/ERK signalling pathway. J Mol Signal (2012) 0.77